Tags

Type your tag names separated by a space and hit enter

Prolonged effect of montelukast in asthmatic children with exercise-induced bronchoconstriction.
Pediatr Pulmonol. 2005 Feb; 39(2):162-6.PP

Abstract

Accumulating evidence shows that cysteinyl leukotrienes are the most important mediators in exercise-induced bronchoconstriction (EIB). In contrast to several studies in adults, there are few long-term studies of leukotriene receptor antagonists (LTRAs) in children with EIB. The aim of this study was to assess the prolonged clinical and bronchoprotective effects of montelukast in asthmatic children with EIB. We randomly assigned 64 asthmatic children with EIB. Forty subjects received montelukast (5 mg/day), and 24 subjects received placebo once daily for 8 weeks. Exercise challenge was performed before and after 8 weeks of treatment. Of the 40 patients in the montelukast group, 28 patients crossed over after 8 weeks. The response was measured as asthma symptom score, maximum percent fall in forced expiratory volume in 1 sec (FEV(1)) from pre-exercise baseline, and time to recovery of FEV(1) to within 10% of pre-exercise baseline (time to recovery). Following 8 weeks of treatment with montelukast, the montelukast group compared with placebo showed significant improvements in all endpoints, including asthma symptom score, maximum percent fall in FEV(1) after exercise, and time to recovery. In the cross-over group, even 8 weeks after stopping montelukast treatment, all endpoints were significantly and persistently improved. These results indicate that montelukast provides clinical protection from airway hyperresponsiveness in asthmatic children with EIB, and suggest that LTRAs may be useful for the long-term management of asthmatic children with EIB.

Authors+Show Affiliations

Department of Pediatrics, Ulsan University Hospital, Ulsan, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

15633203

Citation

Kim, Ja-Hyung, et al. "Prolonged Effect of Montelukast in Asthmatic Children With Exercise-induced Bronchoconstriction." Pediatric Pulmonology, vol. 39, no. 2, 2005, pp. 162-6.
Kim JH, Lee SY, Kim HB, et al. Prolonged effect of montelukast in asthmatic children with exercise-induced bronchoconstriction. Pediatr Pulmonol. 2005;39(2):162-6.
Kim, J. H., Lee, S. Y., Kim, H. B., Kim, B. S., Shim, J. Y., Hong, T. J., & Hong, S. J. (2005). Prolonged effect of montelukast in asthmatic children with exercise-induced bronchoconstriction. Pediatric Pulmonology, 39(2), 162-6.
Kim JH, et al. Prolonged Effect of Montelukast in Asthmatic Children With Exercise-induced Bronchoconstriction. Pediatr Pulmonol. 2005;39(2):162-6. PubMed PMID: 15633203.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prolonged effect of montelukast in asthmatic children with exercise-induced bronchoconstriction. AU - Kim,Ja-Hyung, AU - Lee,So-Yeon, AU - Kim,Hyo-Bin, AU - Kim,Bong-Seong, AU - Shim,Jung-Yeon, AU - Hong,Taek-Jong, AU - Hong,Soo-Jong, PY - 2005/1/6/pubmed PY - 2005/5/25/medline PY - 2005/1/6/entrez SP - 162 EP - 6 JF - Pediatric pulmonology JO - Pediatr Pulmonol VL - 39 IS - 2 N2 - Accumulating evidence shows that cysteinyl leukotrienes are the most important mediators in exercise-induced bronchoconstriction (EIB). In contrast to several studies in adults, there are few long-term studies of leukotriene receptor antagonists (LTRAs) in children with EIB. The aim of this study was to assess the prolonged clinical and bronchoprotective effects of montelukast in asthmatic children with EIB. We randomly assigned 64 asthmatic children with EIB. Forty subjects received montelukast (5 mg/day), and 24 subjects received placebo once daily for 8 weeks. Exercise challenge was performed before and after 8 weeks of treatment. Of the 40 patients in the montelukast group, 28 patients crossed over after 8 weeks. The response was measured as asthma symptom score, maximum percent fall in forced expiratory volume in 1 sec (FEV(1)) from pre-exercise baseline, and time to recovery of FEV(1) to within 10% of pre-exercise baseline (time to recovery). Following 8 weeks of treatment with montelukast, the montelukast group compared with placebo showed significant improvements in all endpoints, including asthma symptom score, maximum percent fall in FEV(1) after exercise, and time to recovery. In the cross-over group, even 8 weeks after stopping montelukast treatment, all endpoints were significantly and persistently improved. These results indicate that montelukast provides clinical protection from airway hyperresponsiveness in asthmatic children with EIB, and suggest that LTRAs may be useful for the long-term management of asthmatic children with EIB. SN - 8755-6863 UR - https://www.unboundmedicine.com/medline/citation/15633203/Prolonged_effect_of_montelukast_in_asthmatic_children_with_exercise_induced_bronchoconstriction_ L2 - https://doi.org/10.1002/ppul.20156 DB - PRIME DP - Unbound Medicine ER -